Thus, combining the CAIX inhibitor, SLC-0111 with paclitaxel or with sunitinib in breast cancer [19,41], with temozolomide in pediatric and adult glioblastoma [42], with gemicitabine in pancreatic cancer [43], or an analog of SLC-0111, FC531, with cytarabine or Quizartinib in acute myeloblastic leukemia (AML) [44], results in greater inhibition of tumor growth and in significant increases in the survival of the tumor bearing mice. This evidence concerns the gene CA9 and neoplasm.